Matt Miksic
Stock Analyst at Barclays
(3.93)
# 632
Out of 5,105 analysts
308
Total ratings
60.42%
Success rate
6.77%
Average return
Main Sectors:
Stocks Rated by Matt Miksic
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EW Edwards Lifesciences | Maintains: Overweight | $99 → $103 | $83.08 | +23.98% | 31 | Dec 8, 2025 | |
| JNJ Johnson & Johnson | Maintains: Equal-Weight | $176 → $197 | $211.58 | -6.89% | 14 | Dec 2, 2025 | |
| MDT Medtronic | Maintains: Overweight | $109 → $111 | $99.87 | +11.14% | 22 | Nov 20, 2025 | |
| OBIO Orchestra BioMed Holdings | Maintains: Overweight | $12 → $11 | $4.51 | +143.90% | 3 | Nov 12, 2025 | |
| TNDM Tandem Diabetes Care | Maintains: Overweight | $51 → $55 | $21.39 | +157.13% | 8 | Nov 10, 2025 | |
| GMED Globus Medical | Maintains: Overweight | $106 → $114 | $86.70 | +31.49% | 16 | Nov 10, 2025 | |
| PODD Insulet | Maintains: Equal-Weight | $301 → $316 | $295.70 | +6.87% | 11 | Nov 7, 2025 | |
| ZBH Zimmer Biomet Holdings | Maintains: Underweight | $105 → $104 | $91.59 | +13.55% | 9 | Nov 6, 2025 | |
| SENS Senseonics Holdings | Maintains: Overweight | $1.5 → $31 | $6.85 | +352.55% | 2 | Nov 5, 2025 | |
| DXCM DexCom | Maintains: Equal-Weight | $98 → $80 | $66.96 | +19.47% | 8 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 → $23 | $19.96 | +15.23% | 4 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $17 | $16.99 | +0.06% | 6 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $443 → $453 | $354.09 | +27.93% | 24 | Oct 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $159 → $162 | $125.46 | +29.12% | 30 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $86 | $83.96 | +2.43% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $85 | $82.08 | +3.56% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $86 | $78.80 | +9.14% | 10 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $133 → $136 | $92.58 | +46.90% | 19 | Oct 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $3.5 | $1.31 | +167.18% | 1 | Aug 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $55 → $58 | $62.75 | -7.57% | 8 | Aug 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $41 → $36 | $19.15 | +87.99% | 22 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $24 → $21 | $14.51 | +44.73% | 14 | Jul 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $261 → $241 | $200.89 | +19.97% | 1 | Jun 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $684 → $635 | $542.32 | +17.09% | 7 | Apr 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $4.98 | +341.77% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $100 | $76.55 | +30.63% | 8 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $722 → $418 | $165.43 | +152.67% | 3 | May 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $28 | $16.83 | +66.37% | 2 | Mar 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $67 | $11.57 | +479.08% | 1 | Mar 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $480 | $2.56 | +18,650.00% | 1 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $84 → $87 | $13.42 | +548.29% | 14 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $25 | $4.82 | +418.67% | 5 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $9 | $7.23 | +24.48% | 1 | Dec 12, 2016 |
Edwards Lifesciences
Dec 8, 2025
Maintains: Overweight
Price Target: $99 → $103
Current: $83.08
Upside: +23.98%
Johnson & Johnson
Dec 2, 2025
Maintains: Equal-Weight
Price Target: $176 → $197
Current: $211.58
Upside: -6.89%
Medtronic
Nov 20, 2025
Maintains: Overweight
Price Target: $109 → $111
Current: $99.87
Upside: +11.14%
Orchestra BioMed Holdings
Nov 12, 2025
Maintains: Overweight
Price Target: $12 → $11
Current: $4.51
Upside: +143.90%
Tandem Diabetes Care
Nov 10, 2025
Maintains: Overweight
Price Target: $51 → $55
Current: $21.39
Upside: +157.13%
Globus Medical
Nov 10, 2025
Maintains: Overweight
Price Target: $106 → $114
Current: $86.70
Upside: +31.49%
Insulet
Nov 7, 2025
Maintains: Equal-Weight
Price Target: $301 → $316
Current: $295.70
Upside: +6.87%
Zimmer Biomet Holdings
Nov 6, 2025
Maintains: Underweight
Price Target: $105 → $104
Current: $91.59
Upside: +13.55%
Senseonics Holdings
Nov 5, 2025
Maintains: Overweight
Price Target: $1.5 → $31
Current: $6.85
Upside: +352.55%
DexCom
Nov 3, 2025
Maintains: Equal-Weight
Price Target: $98 → $80
Current: $66.96
Upside: +19.47%
Nov 3, 2025
Maintains: Overweight
Price Target: $22 → $23
Current: $19.96
Upside: +15.23%
Oct 31, 2025
Maintains: Equal-Weight
Price Target: $16 → $17
Current: $16.99
Upside: +0.06%
Oct 22, 2025
Maintains: Overweight
Price Target: $443 → $453
Current: $354.09
Upside: +27.93%
Oct 17, 2025
Maintains: Overweight
Price Target: $159 → $162
Current: $125.46
Upside: +29.12%
Oct 13, 2025
Initiates: Equal-Weight
Price Target: $86
Current: $83.96
Upside: +2.43%
Oct 13, 2025
Initiates: Overweight
Price Target: $85
Current: $82.08
Upside: +3.56%
Oct 13, 2025
Initiates: Equal-Weight
Price Target: $86
Current: $78.80
Upside: +9.14%
Oct 2, 2025
Maintains: Overweight
Price Target: $133 → $136
Current: $92.58
Upside: +46.90%
Aug 27, 2025
Initiates: Overweight
Price Target: $3.5
Current: $1.31
Upside: +167.18%
Aug 21, 2025
Maintains: Equal-Weight
Price Target: $55 → $58
Current: $62.75
Upside: -7.57%
Aug 4, 2025
Maintains: Overweight
Price Target: $41 → $36
Current: $19.15
Upside: +87.99%
Jul 30, 2025
Maintains: Overweight
Price Target: $24 → $21
Current: $14.51
Upside: +44.73%
Jun 3, 2025
Maintains: Overweight
Price Target: $261 → $241
Current: $200.89
Upside: +19.97%
Apr 24, 2025
Maintains: Overweight
Price Target: $684 → $635
Current: $542.32
Upside: +17.09%
Jan 7, 2025
Initiates: Overweight
Price Target: $22
Current: $4.98
Upside: +341.77%
May 13, 2022
Assumes: Outperform
Price Target: $100
Current: $76.55
Upside: +30.63%
May 4, 2022
Maintains: Outperform
Price Target: $722 → $418
Current: $165.43
Upside: +152.67%
Mar 2, 2022
Maintains: Outperform
Price Target: $31 → $28
Current: $16.83
Upside: +66.37%
Mar 1, 2022
Maintains: Outperform
Price Target: $68 → $67
Current: $11.57
Upside: +479.08%
Jan 7, 2022
Initiates: Outperform
Price Target: $480
Current: $2.56
Upside: +18,650.00%
Nov 3, 2021
Maintains: Outperform
Price Target: $84 → $87
Current: $13.42
Upside: +548.29%
Aug 10, 2021
Maintains: Outperform
Price Target: $24 → $25
Current: $4.82
Upside: +418.67%
Dec 12, 2016
Initiates: Sell
Price Target: $9
Current: $7.23
Upside: +24.48%